In order to avoid the consequences of over- and under-treatment of endometrial hyperplasia, diagnostic accuracy and progression risk assessment must be improved. The aim of this study was to assess whether PAX2 or PTEN expression could predict progression-free survival in endometrial intraepithelial neoplasia (EIN) and endometrial endometrioid carcinoma (EEC). Immunohistochemistry for detection of PAX2 and PTEN was performed on 348 endometrial samples; 75 proliferative endometrium (PE), 36 EIN and 237 EEC. Cases classified as PTEN null (1 or more glands negatively stained) were more prevalent in EEC than in PE and EIN (64% EEC vs 11% PE/EIN). A progressive decrease in PAX2 expression was observed from PE to EIN to EEC. Long-term clinical follow-up (6–310 months, median: 126) was available for 62 PE cases, all 36 EIN cases and 178 EEC cases. No patients with PE demonstrated progression to EIN or EEC. Progression of disease was observed in 10 (28%) EIN patients. These patients had significantly lower PAX2 expression than those that regressed (P = 0.005). Progression-free survival analysis revealed that EIN patients with a high-risk PAX2 expression score (H-score ≤75) had a higher probability of progression of disease in comparison to those with a low-risk score (H-score >75). PAX2 expression was not prognostic in EEC nor was PTEN status of prognostic value in either EIN or EEC. PAX2 expression analysis by means of H-score has prognostic potential for the identification of high-risk progression cases in EIN but needs to be validated in a larger cohort.
Akiyama-AbeAMinaguchiTNakamuraYMichikamiHShikamaANakaoSSakuraiMOchiHOnukiMMatsumotoKet al. 2013Loss of PTEN expression is an independent predictor of favourable survival in endometrial carcinomas. British Journal of Cancer1091703–1710. (https://doi.org/10.1038/bjc.2013.455)
AllisonKHUpsonKReedSDJordanCDNewtonKMDohertyJSwisherEMGarciaRL2012PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia. International Journal of Gynecological Pathology31151–159. (https://doi.org/10.1097/PGP.0b013e318226b376)
BaakJPAØrboAVan DiestPJJiwaMde BruinPBroeckaertMSnijdersWBoodtPJFonsGBurgerCet al. 2001Prospective multicenter evaluation of the mophometric D-score for prediction of the outcome of endometrial hyperplasias. American Journal of Surgical Pathology25930–935.
BaakJPMutterGLRobboySvan DiestPJUyterlindeAMØrboAPalazzoJFianneBLøvslettKBurgerCet al. 2005aThe molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization Classification System. Cancer1032304–2312. (https://doi.org/10.1002/cncr.21058)
BaakJPAvan DiermenBSteinbakkAJanssenESkalandIMutterGLFianeBLøvslettK2005bLack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression. Human Pathology36555–561. (https://doi.org/10.1016/j.humpath.2005.02.018)
BergeronCNogalesFFMasseroliMAbelerVDuvillardPMüller-HolznerEPickartzHWellsM1999A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. American Journal of Surgical Pathology231102–1108. (https://doi.org/10.1097/00000478-199909000-00014)
DaniilidouKFrangou-PlemenouMGrammatikakisJGrigoriouOVitoratosNKondi-PafitiA2013Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study. Journal of the Balkan Union of Oncology18195–201.
FengZ-ZChenJ-WYangZ-RLuG-ZCaiZ-G2012Expression of PTTG1 and PTEN in endometrial carcinoma: correlation with tumorigenesis and progression. Medical Oncology29304–310. (https://doi.org/10.1007/s12032-010-9775-x)
HechtJLInceTABaakJPBakerHEOgdenMWMutterGL2005Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Modern Pathology18324–330. (https://doi.org/10.1038/modpathol.3800328)
JoinerAKQuickCMJeffusSK2015PAX2 expression in simultaneously diagnosed WHO and EIN classification systems. International Journal of Gynecological Pathology3440–46. (https://doi.org/10.1097/PGP.0000000000000185)
KahramanKKiremitciSTaskinSKankayaDSertcelikAOrtacF2012Expression pattern of PAX2 in hyperplastic and malignant endometrium. Archives of Gynecology and Obstetrics286173–178. (https://doi.org/10.1007/s00404-012-2236-3)
KanamoriYKigawaJItamochiHSultanaHSuzukiMOhwadaMKamuraTSugiyamaTKikuchiYKitaT2002PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy. International Journal of Cancer100686–689. (https://doi.org/10.1002/ijc.10542)
KendallBSRonnettBMIsacsonCChoKRHedrickLDiener-WestMKurmanRJ1998Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. American Journal of Surgical Pathology221012–1019.
KuroseKZhouX-PArakiTCannistraSAMaherEREngC2001Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. American Journal of Pathology1582097–2106. (https://doi.org/10.1016/S0002-9440(10)64681-0)
LaceyJVMutterGLRonnettBMIoffeOBDugganMARushBBGlassAGRichessonDAChatterjeeNLangholzBet al. 2008PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Research686014–6020. (https://doi.org/10.1158/0008-5472.CAN-08-1154)
LeeHChoiHJKangCSLeeHJLeeWSParkCS2012Expression of miRNAs and PTEN in endometrial specimens ranging from histologically normal to hyperplasia and endometrial adenocarcinoma. Modern Pathology251508–1515. (https://doi.org/10.1038/modpathol.2012.111)
MackayHJGallingerSTsaoMSMcLachlinCMTuDKeiserKEisenhauerEAOzaAM2010Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG). European Journal of Cancer461365–1373. (https://doi.org/10.1016/j.ejca.2010.02.031)
MutterGLLinM-CFitzgeraldJTKumJBBaakJLeesJAWengL-PEngC2000Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. Journal of the National Cancer Institute92924–930. (https://doi.org/10.1093/jnci/92.11.924)
PavlakisKMessiniIVrekoussisTPanoskaltsisTChrissanthakisDYiannouPStathopoulosEN2010PTEN-loss and nuclear atypia of EIN in endometrial biopsies can predict the existence of a concurrent endometrial carcinoma. Gynecologic Oncology119516–519. (https://doi.org/10.1016/j.ygyno.2010.08.023)
QuickCMLauryARMonteNMMutterGL2012Utility of PAX2 as a marker for diagnosis of endometrial intraepithelial neoplasia. American Journal of Clinical Pathology138678–684. (https://doi.org/10.1309/AJCP8OMLT7KDWLMF)
SkovBBroholmHEngelUFranzmannM-BNielsenALauritzenASkovT1997Comparison of the reproducibility of the WHO classifications of 1975 and 1994 of endometrial hyperplasia. International Journal of Gynecological Pathology1633–37. (https://doi.org/10.1097/00004347-199701000-00006)
SteinbakkASkalandIGudlaugssonEJanssenEAKjellevoldKHKlosJLøvslettKFianeBBaakJP2009The prognostic value of molecular biomarkers in tissue removed by curettage from FIGO stage 1 and 2 endometrioid type endometrial cancer. American Journal of Obstetrics and Gynecology20078.e71–78.e78. (https://doi.org/10.1016/j.ajog.2008.07.020)
StrisselPLEllmannSLoprichEThielFFaschingPAStieglerEHartmannABeckmannMWStrickR2008Early aberrant insulin‐like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen. International Journal of Cancer1232871–2879. (https://doi.org/10.1002/ijc.23900)
UegakiKKanamoriYKigawaJKawaguchiWKanekoRNaniwaJTakahashiMShimadaMOishiTItamochiHet al. 2005PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. Oncology Reports14389–392.
UpsonKAllisonKHReedSDJordanCDNewtonKMSwisherEMDohertyJAGarciaRL2012Biomarkers of progestin therapy resistance and endometrial hyperplasia progression. American Journal of Obstetrics and Gynecology20736.e31–36.e38. (https://doi.org/10.1016/j.ajog.2012.05.012)
UsubutunAMutterGLSaglamADolgunAOzkanEAInceTAkyolABulbulHDCalayZErenFet al. 2012Reproducibility of endometrial intraepithelial neoplasia diagnosis is good, but influenced by the diagnostic style of pathologists. Modern Pathology25877–884. (https://doi.org/10.1038/modpathol.2011.220)
YangHPMeekerAGuidoRGunterMJHuangGSLuhnPd’AmbrosioLWentzensenNShermanME2015PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors. Cancer Causes and Control261729–1736. (https://doi.org/10.1007/s10552-015-0666-5)